|
Name |
Thiocladospolide I
|
Molecular Formula | C27H44O10S | |
IUPAC Name* |
(4S,11R)-4-hydroxy-11-[(2S)-2-hydroxy-3-[[(3S,6S,12R)-6-hydroxy-12-methyl-2,5-dioxo-oxacyclododec-3-yl]sulfanyl]propanoyl]oxydodec-2-enoic acid
|
|
SMILES |
C[C@@H]1CCCCC[C@@H](C(=O)C[C@@H](C(=O)O1)SC[C@H](C(=O)O[C@H](C)CCCCCC[C@@H](C=CC(=O)O)O)O)O
|
|
InChI |
InChI=1S/C27H44O10S/c1-18(10-6-3-4-8-12-20(28)14-15-25(32)33)36-26(34)23(31)17-38-24-16-22(30)21(29)13-9-5-7-11-19(2)37-27(24)35/h14-15,18-21,23-24,28-29,31H,3-13,16-17H2,1-2H3,(H,32,33)/t18-,19-,20+,21+,23-,24+/m1/s1
|
|
InChIKey |
WNKIJOAGEYHZFZ-BXFVOWPLSA-N
|
|
Synonyms |
Thiocladospolide I
|
|
CAS | NA | |
PubChem CID | 156582698 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 560.7 | ALogp: | 3.5 |
HBD: | 4 | HBA: | 11 |
Rotatable Bonds: | 15 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 193.0 | Aromatic Rings: | 1 |
Heavy Atoms: | 38 | QED Weighted: | 0.139 |
Caco-2 Permeability: | -5.42 | MDCK Permeability: | 0.00001600 |
Pgp-inhibitor: | 0.945 | Pgp-substrate: | 0.946 |
Human Intestinal Absorption (HIA): | 0.015 | 20% Bioavailability (F20%): | 0.875 |
30% Bioavailability (F30%): | 0.923 |
Blood-Brain-Barrier Penetration (BBB): | 0.073 | Plasma Protein Binding (PPB): | 88.04% |
Volume Distribution (VD): | 0.361 | Fu: | 5.30% |
CYP1A2-inhibitor: | 0.025 | CYP1A2-substrate: | 0.04 |
CYP2C19-inhibitor: | 0.013 | CYP2C19-substrate: | 0.047 |
CYP2C9-inhibitor: | 0.047 | CYP2C9-substrate: | 0.992 |
CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.08 |
CYP3A4-inhibitor: | 0.024 | CYP3A4-substrate: | 0.023 |
Clearance (CL): | 5.606 | Half-life (T1/2): | 0.931 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.425 |
Drug-inuced Liver Injury (DILI): | 0.69 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.064 | Maximum Recommended Daily Dose: | 0.969 |
Skin Sensitization: | 0.341 | Carcinogencity: | 0.241 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.017 |
Respiratory Toxicity: | 0.05 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004422 | 0.699 | D0I4DQ | 0.311 | ||||
ENC004419 | 0.551 | D0N3NO | 0.299 | ||||
ENC002048 | 0.457 | D06FEA | 0.281 | ||||
ENC003570 | 0.427 | D0ZI4H | 0.280 | ||||
ENC004420 | 0.414 | D0V0IX | 0.279 | ||||
ENC002063 | 0.376 | D0X8KY | 0.253 | ||||
ENC004708 | 0.374 | D03KYG | 0.241 | ||||
ENC003308 | 0.374 | D03JSJ | 0.235 | ||||
ENC004418 | 0.327 | D0D9NY | 0.228 | ||||
ENC004121 | 0.325 | D09ANG | 0.228 |